Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Current Deferred Revenue (2020 - 2022)

Neuroone Medical Technologies filings provide 3 years of Current Deferred Revenue readings, the most recent being $1.5 million for Q3 2022.

  • On a quarterly basis, Current Deferred Revenue rose 16777.62% to $1.5 million in Q3 2022 year-over-year; TTM through Sep 2022 was $1.5 million, a 16777.62% increase, with the full-year FY2022 number at $1.5 million, up 16777.62% from a year prior.
  • Current Deferred Revenue hit $1.5 million in Q3 2022 for Neuroone Medical Technologies, up from $2248.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.5 million in Q3 2022 to a low of $2248.0 in Q4 2021.
  • Median Current Deferred Revenue over the past 3 years was $13596.0 (2021), compared with a mean of $182199.0.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 95.61% in 2021 and later soared 16777.62% in 2022.
  • Neuroone Medical Technologies' Current Deferred Revenue stood at $51160.0 in 2020, then plummeted by 95.61% to $2248.0 in 2021, then skyrocketed by 64632.56% to $1.5 million in 2022.
  • The last three reported values for Current Deferred Revenue were $1.5 million (Q3 2022), $2248.0 (Q2 2022), and $2248.0 (Q1 2022) per Business Quant data.